Last reviewed · How we verify
NCT07177703
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
Phase 2 trial testing Treprostinil in Pulmonary Arterial Hypertension (PAH) in 32 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 31 October 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Treprostinil (TREPROSTINIL) — full drug profile →
Conditions studied
- Pulmonary Arterial Hypertension (PAH) — all drugs for Pulmonary Arterial Hypertension (PAH) →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 75, any sex, with Pulmonary Arterial Hypertension (PAH). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their heart function can continue to decline. This study aims to find out if adding an injectable medication, Treprostinil, to a patient's current oral PAH therapy can improve heart function and overall health. This is a single-arm study, which means all participants will receive the study treatment. The main goal is to measure the change in the amount of blood the right side of the heart pumps with each beat (Right Ventricular Stroke Volume, or RVSV) after 3 months of treatment. This will be measured using a specialized heart scan called Cardiac Magnetic Resonance Imaging (CMR). Researchers will also assess changes in exercise ability (with a 6-minute walk test), blood markers, and patient symptoms. Participants will be in the main part of the study for 3 months, with follow-up for a total of 24 months to monitor the long-term effects and safety of the treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07177703
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Treprostinil
Trials testing the same drug.
- NCT06603285 — A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin · not yet recruiting
- NCT05564637 — A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension · Phase 2 · completed
- NCT05067270 — A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus · Phase 1 · completed
- NCT04005469 — Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation · Phase 1, PHASE2 · recruiting
- NCT03835676 — Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension · Phase 4 · unknown
Other recruiting trials for Pulmonary Arterial Hypertension (PAH)
Currently open trials in the same condition.
- NCT07245680 — COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities · Phase 3 · recruiting
- NCT06872112 — A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension · Phase 1 · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT07457762 — AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? · NA · recruiting
- NCT06941441 — PAH Exercise Study · Phase 3 · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07177703 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 17 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07177703.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing